Skip to main content

Table 1 Baseline characteristics (on study day) of healthy subjects included in this trial

From: Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial

Baseline characteristics Median (IQR) 001 002 003 004 005 006 007 008 009 010 011 012
Age - years 32 (24.5–40.5) 24 26 29 41 31 51 39 22 21 56 33 35
Female sex [no.] 4 (8 males) 0 1 1 1 1 0 0 0 0 0 0 0
Weight - kilogram 69 (59–77) 76 58 60 59 58 70 76 68 77 86 64 91,5
Ethnicity caucasian = c, black = b, asian = a c c c c c b c a c c c c
Vital parameters
 RR systolic - mmHg 133 (128–146) 147 107 129 112 136 143 147 128 130 157 140 128
 RR diastolic - mmHg 79 (73–88.5) 80 68 78 72 87 97 95 76 78 89 71 82
 Heart rate - bpm 79 (70–84) 80 82 61 53 79 87 69 84 78 76 84 74
 SpO2 - % 98 (97–99) 99 99 100 99 98 95 97 98 98 98 99 97
 Temperature (axilla) – degree celsius (°C) 36.0 (35.6–36.1) 35,8 36,4 36 36,1 36,3 35,7 35,5 35 35,5 36,0 36,0 35,9
PLT count (× 109)a 263 (224–281) 285 291 219 281 280 160 240 247 256 216 270 276
MEA ADP - U 68 (59–86) 74 68 96 73 99 39b 62 58 60 51 90 68
  1. PLT platelet, MEA multiple electrode aggregometry, ADP adenosine diphosphate, RR Riva-Rocci ≈ blood pressure, bpm beats per minute, SpO2 peripheral oxygen saturation, IQR interquartile range)
  2. a Measured at screening visit
  3. b Healthy subject 006 presented with an initial ADP-induced platelet aggregation of 39 U, which is already within the therapeutic range. ADP-induced platelet aggregation re-increased to 50 U at 60 min after the first bolus infusion of cangrelor and peaked at 64 U just before the following cangrelor bolus infusion. Potential causes of the initial low level of ADP-induced platelet aggregation could involve a false-low measurement or diurnal variation of platelet function. ADP-induced platelet aggregation is also influenced by variations in platelet count, even within the physiological range [44]